More rare disease drugs must also be approved, says EURORDIS.
Top tips for ‘digitally cautious’ pharma.
An innovative programme is being rolled out across Kenya.
Understand the habits and preferences of target markets in detail with AI.
Research shows industry needs to see more evidence of success for wider adoption.
What changes will STPs bring and what are the implications for pharma?
Proactive and included patients can help clinical trial retention.
Examining the views of different stakeholders in the ecosystem supporting drug R&D.